### Chloroquine

**Section:** 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines

**Indication:** Malaria due to *Plasmodium falciparum*

**INN:** Chloroquine

**Medicine type:** Chemical agent

**List type:** Core

**Formulations:**
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

**EML status history:**
- First added in 1987 (TRS 770)
- Removed in 2007 (TRS 946)

**Sex:** All

**Age:** Adolescents and adults

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

**Wikipedia:** Chloroquine

**DrugBank:** Chloroquine

### Summary of evidence and Expert Committee recommendations

Chloroquine was maintained on the core list for prophylaxis to limit the use of chloroquine to central American regions and for prophylaxis of *P. vivax*, *P. ovale* and *P. malariae* infections.